Lipigon Pharmaceuticals AB (publ) (STO:LPGO)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.0030
-0.0002 (-6.25%)
Apr 24, 2026, 5:04 PM CET

STO:LPGO Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-10.2916.41-2.21
Revenue Growth (YoY)
--37.30%---44.86%
Cost of Revenue
22.8428.721.5231.6638.25
Gross Profit
-22.84-18.41-5.12-31.66-36.04
Selling, General & Admin
8.857.817.446.075.44
Other Operating Expenses
0.530.640.870.390.69
Operating Expenses
9.468.518.336.486.12
Operating Income
-32.29-26.93-13.45-38.13-42.16
Interest Expense
-0.22-0.06-0--0.01
Interest & Investment Income
-0.380.250.040.08
Currency Exchange Gain (Loss)
0.071.351.070.39-
Other Non Operating Income (Expenses)
0-0-0.97
EBT Excluding Unusual Items
-32.44-25.26-12.13-37.71-41.11
Pretax Income
-32.44-25.26-12.13-37.71-41.11
Net Income
-32.44-25.26-12.13-37.71-41.11
Net Income to Common
-32.44-25.26-12.13-37.71-41.11
Shares Outstanding (Basic)
40413864159
Shares Outstanding (Diluted)
40413864159
Shares Change (YoY)
191.76%115.86%336.30%63.10%104.09%
EPS (Basic)
-0.08-0.18-0.19-2.57-4.56
EPS (Diluted)
-0.08-0.18-0.19-2.57-4.56
Free Cash Flow
-35.88-25.02-14.32-37.47-35.42
Free Cash Flow Per Share
-0.09-0.18-0.22-2.55-3.93
Gross Margin
--179.00%-31.19%--
Operating Margin
--261.74%-81.95%--1906.83%
Profit Margin
--245.59%-73.92%--1859.48%
Free Cash Flow Margin
--243.18%-87.27%--1601.94%
EBITDA
-32.21-26.87-13.42-38.11-42.14
EBITDA Margin
--261.16%-81.81%--
D&A For EBITDA
0.080.060.020.020.02
EBIT
-32.29-26.93-13.45-38.13-42.16
EBIT Margin
--261.74%-81.95%--
Revenue as Reported
0.0711.6417.480.393.18
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.